CKS1BP7: A Potential Drug Target and Biomarker (G137529)

Target Name: CKS1BP7

NCBI ID: G137529

CKS1BP7

Other Name(s): CKS1A | CKS1 | CDC28 protein kinase regulatory subunit 1B pseudogene 7

CKS1BP7: A Potential Drug Target and Biomarker

CKS1BP7, also known as Kallikrein-related peptidase 1-beta (KLK1尾), is a protein that is expressed in various tissues, including the brain, heart, kidneys, and intestines. It is a member of the serine proteases, or enzyme, family 1A, which includes other well-known proteins such as thrombin, trypsin, and chymotrypsin. CKS1BP7 is involved in the regulation of proteolytic enzymes, which are enzymes that break down other proteins.

One of the unique aspects of CKS1BP7 is its ability to regulate the activity of other proteases. It does this by forming a covalent complex with the protease, which in turn is able to activate the protease and promote its activity. This regulation is critical for many cellular processes, including cell signaling, tissue repair, and inflammation.

CKS1BP7 has also been shown to play a role in the development and progression of certain diseases. For example, it has been associated with the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as with the development of certain cancers. Additionally, it has been shown to be involved in the regulation of pain perception, which may contribute to its potential as a drug target for pain management.

CKS1BP7 is also a potential biomarker for certain diseases. For example, it has been shown to be elevated in the blood of people with Alzheimer's disease, which may be a diagnostic marker for this disease. Additionally, it has been shown to be elevated in the urine of people with Parkinson's disease, which may be a diagnostic marker for this disease as well.

CKS1BP7 is also a potential drug target for several diseases, including cancer, neurodegenerative diseases, and pain management. For example, researchers have shown that inhibiting the activity of CKS1BP7 using small molecules or antibodies can lead to the inhibition of cancer cell growth and the regression of neurodegenerative diseases. Additionally, CKS1BP7 has been shown to be involved in the regulation of pain perception, which may be a potential target for pain management.

In conclusion, CKS1BP7 is a protein that is involved in the regulation of proteolytic enzymes and has been associated with the development and progression of various diseases. It is also a potential drug target for cancer, neurodegenerative diseases, and pain management. Further research is needed to fully understand the role of CKS1BP7 in these processes and to develop effective treatments.

Protein Name: CDC28 Protein Kinase Regulatory Subunit 1B Pseudogene 7

The "CKS1BP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKS1BP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets